文献速递造血干细胞移植与细胞治疗

维多珠单抗预防异基因造血干细胞移植后移植物抗宿主病

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

这项1b期开放标签剂量探索研究在24例接受allo-HSCT的成人中评估维多珠单抗预防aGVHD的耐受性、安全性和药代动力学。75mg组3例、300mg组21例均未观察到剂量限制性毒性,300mg组100天内II-IV级aGVHD发生率为19.0%,整体及下消化道aGVHD发生率低,支持进一步评估。

要点

  • 维多珠单抗75mg和300mg剂量均未观察到剂量限制性毒性。
  • 300mg组100天内II-IV级aGVHD发生率为19.0%(4/21)。
  • 维多珠单抗300mg静脉给药作为aGVHD预防耐受性良好。

核心结论

  • 维多珠单抗静脉300mg作为aGVHD预防耐受性良好,整体及下消化道aGVHD发生率低,支持在该人群中进一步评估。

研究设计与样本

  • 1b期开放标签剂量探索研究,纳入24例接受allo-HSCT的成人,维多珠单抗于移植前第-1天、+13天和+42天静脉给药,起始75mg并按耐受性和药代动力学递增剂量。

主要发现

  • 75mg组(n=3)和剂量递增至300mg组(n=21)均未观察到剂量限制性毒性。
  • 8例参与者发生与维多珠单抗相关的治疗中出现的不良事件。
  • allo-HSCT后12个月内共发生4例死亡。
  • 75mg组无参与者在allo-HSCT后100天内发生改良Glucksberg II-IV级aGVHD。
  • 300mg组4例参与者(19.0%)在allo-HSCT后100天内发生II-IV级aGVHD,其中3例发生下消化道1期aGVHD。

临床怎么用

  • 维多珠单抗300mg静脉给药可作为allo-HSCT后aGVHD的预防策略进行进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) remains a significant complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria. We carried out a phase 1b, open-label, dose-finding study in adults undergoing allo-HSCT to evaluate the tolerability, safety, and pharmacokinetics of vedolizumab, and its effectiveness in reducing aGVHD. IV vedolizumab was administered on day -1, +13, and +42 with respect to allo-HSCT, starting at 75 mg and with dose escalation guided by tolerability and pharmacokinetics. A total of 24 participants was enrolled, and no dose-limiting toxicities were observed in either the 75-mg cohort (n = 3) or the dose-escalated 300-mg cohort (n = 21). Treatment-emergent adverse events related to vedolizumab occurred in 8 participants. Overall, 4 deaths occurred during the 12 months following allo-HSCT. No participants in the 75-mg cohort developed modified Glucksberg grade II to IV aGVHD by 100 days after allo-HSCT. Four participants (19.0%) in the 300-mg cohort developed grade II to IV aGVHD by 100 days after allo-HSCT, including 3 participants who developed stage 1 aGVHD of the lower-intestinal tract. Vedolizumab IV 300 mg was well tolerated as aGVHD prevention, and the incidence of overall and lower-intestinal aGVHD was low. These findings support further evaluation of vedolizumab in this patient population. This trial was registered at www.clinicaltrials.gov as #NCT02728895.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chen YB, Shah NN, Renteria AS, et al. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019. PMID: 31821456. doi:10.1182/bloodadvances.2019000893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。